Global (English)
Website: https://www.miolive.eu/
MIOLive 2026 is an international congress dedicated to the advancement of interventional oncology, with a specific focus on the Mediterranean region and a strong global outlook. Taking place in Rome on January 26–27, 2026, the event is designed as a multidisciplinary platform where innovation, clinical practice, and research converge to address the evolving challenges of oncologic care.
In a rapidly developing field shaped by technological progress and expanding therapeutic options, MIOLive 2026 promotes a comprehensive and integrated approach to patient management. The congress brings together interventional radiologists, oncologists, surgeons, hepatologists, and researchers to foster knowledge exchange, collaborative decision-making, and the translation of scientific innovation into everyday clinical practice.
The scientific programme covers key areas in interventional oncology, including the management of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, with attention to curative and palliative strategies, imaging advancements, minimally invasive procedures, and emerging systemic therapies. Special focus is given to the role of artificial intelligence and big data in diagnosis, treatment planning, and predictive modeling, alongside discussions on ethics, safety, and reliability.
Live case sessions and interactive panels form a central part of the congress, offering practical insights into new devices, techniques, and locoregional treatments, while encouraging dialogue across specialties. By combining real-world experience with cutting-edge research, MIOLive 2026 aims to support evidence-based practice, enhance clinical skills, and contribute to the future development of interventional oncology, ultimately improving outcomes and personalization of care for patients with intrahepatic and related cancers.
